Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenticonazole is an imidazole antifungal drug primarily used topically as the nitrate salt for the treatment of vulvovaginal candidiasis and other superficial fungal infections. It exhibits a broad spectrum of activity against dermatophytes, yeasts (including Candida albicans), and some gram-positive bacteria such as Staphylococcus aureus. Fenticonazole also demonstrates antiparasitic action against Trichomonas vaginalis. Its mechanism of action involves inhibition of ergosterol synthesis—an essential component for fungal cell membrane integrity—by blocking fungal cytochrome P450-dependent enzymes that convert lanosterol to ergosterol. Additionally, it inhibits oxidizing enzymes (oxidases and peroxidases), leading to accumulation of toxic peroxides and necrosis in fungal cells. The drug also increases membrane permeability in bacteria and inhibits pyruvate oxido-reductase in protozoa, contributing to its antibacterial and antiprotozoal effects[1][3][6][7]. Fenticonazole is available in various topical formulations including creams, sprays, ovules, and vaginal capsules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fenticonazole.